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RadiosensitizerGlioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to
date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolo
mide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform
treatment schedules.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).Background
Glioblastoma (GBM) is the most common primary malignant
brain tumour and carries the worst prognosis: median survival is
12–18 months and 2-year survival rates approximately 25% [2].
Incidence is increasing, with over 2-500 cases diagnosed in the
UK each year [1]. Patients aged under 70 withWorld Health Organ-
isation (WHO) performance status 0–1 are treated with debulking
surgery where possible followed by radical radiotherapy with con-
comitant and adjuvant temozolomide. Benefit from temozolomide
is limited to patients whose tumours exhibit methylation of the
MGMT promoter region [3], and the acceptability of withholdingtemozolomide from patients with MGMT unmethylated tumours
in the context of clinical trials has been validated. This approach
is particularly valuable when an investigational agent is expected
to increase the toxic effects of temozolomide, or vice versa.
Attempts to improve outcomes in GBM by increasing radiation
dose have been unsuccessful, so recent trials have intensified
chemotherapy or added molecular targeted agents to standard
radio-chemotherapy. The negative results of multiple phase II
and III trials support the viewpoint that molecular targeted agents
inhibiting specific signaling pathways are generally ineffective
against this heterogeneous disease [4–6]. Furthermore, the mea-
surable incidence of late neurotoxicity in these patients indicates
that strategies aimed at intensifying treatment must be robustly
tumour specific [7–9].
PARADIGM-2 aims to improve treatment of GBM patients by
combining conventional radio-chemotherapy with pharmacologi-
cal inhibition of the DNA damage response (DDR) using olaparib,
on orally bioavailable inhibitor of poly(ADP-ribose) polymerase
(PARP). PARP is an abundant nuclear protein involved in detection
and repair of DNA breaks induced by ionising radiation or DNA
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expressed in GBM [10] but barely detectable in the normal brain.
The radiosensitising effects of PARP inhibition have been demon-
strated in multiple glioma cell lines [11], and are observed only
in actively dividing cells. Since normal brain tissue is composed
almost exclusively of non-dividing cells, combining radiotherapy
with PARP inhibitors is predicted to enhance its therapeutic ratio
[12–15]. In contrast, combining PARP inhibition with temozolo-
mide is known to exacerbate dose-limiting haematological toxicity
[16,17]. However our recent dose escalation study of olaparib plus
temozolomide in patients with recurrent GBM showed that inter-
mittent olaparib (three days per week) can safely be combined
with full dose temozolomide given daily for 42 days. We will
therefore introduce olaparib on an intermittent schedule in the
MGMT methylated patient group. For patients in the MGMT
unmethylated group, omission of temozolomide will enable con-
tinuous olaparib treatment and facilitate dose escalation with min-
imal risk of haematological toxicity.
PARP activation is also strongly implicated in the pathogenesis
of neuroinflammation: numerous studies have shown that inhibi-
tion of PARP protects the healthy brain from a range of neurotoxic
insults [18]. Since radiation-induced neuroinflammation is a key
contributor to the acute, subacute and late phases of neurotoxicity
[19], we hypothesized that olaparib might protect the normal brain
from the adverse effects of radiation and it was agreed that a four
week period of olaparib treatment post-radiotherapy was justified.Fig. 1. Study design fMethods and study design
PARADIGM-2 study is co-sponsored by the University of Glas-
gow and NHS Greater Glasgow and Clyde. It is funded by Cancer
Research UK (CRUK), The Brain Tumour Charity and AstraZeneca
under the terms of the Combinations Alliance collaboration
between the CRUK Centre for Drug Development and the Experi-
mental Cancer Medicines Network (ECMC). The study has received
National Research Ethics Committee approval.
This is a multi-centre, open-label, non-randomised, dose-
escalation phase I clinical trial of olaparib in combination with
radiotherapy, with or without temozolomide, in patients with
newly diagnosed GBM. There are two parallel groups within one
trial protocol (Fig. 1).
Patients allocated to parallel 1 (MGMT methylated) will receive
standard radical radiotherapy (60 Gy in 30 fractions over 6 weeks)
and concomitant temozolomide chemotherapy (75 mg/m2 daily
throughout radiotherapy) in combination with olaparib, followed
immediately by a further 4 week period of olaparib given at the
same dose and schedule as during radiotherapy. Olaparib treat-
ment will be intermittent and the daily dose and schedule will
be escalated based on a 3 + 3 phase I design. Patients will then
receive adjuvant temozolomide as per standard care. The dose
escalation strategy is shown in Table 1.
Patients allocated to parallel II of the study (MGMT unmethy-
lated) will receive radical radiotherapy (60 Gy in 30 fractions overor PARADIGM-2.
Table 1
Dose escalation strategy for MGMT methylated patients.
Dose
level
Olaparib Dose starting day 1 of
radio-chemotherapy and
continuing until 4 weeks after end
of radio-chemotherapy
Temozolomide Dose starting
day 1 and continuing daily for 6
weeks of radio-chemotherapy
1 50 mg single dose
Day 1 of each week
75 mg/m2 once daily
1 100 mg single dose
Day 1 of each week
75 mg/m2 once daily
2 100 mg once daily
Days 1 and 2 of each week
75 mg/m2 once daily
3 100 mg once daily
Days 1–3 of each week
75 mg/m2 once daily
4 150 mg once daily
Days 1–3 of each week
75 mg/m2 once daily
5 150 mg once daily
Days 1–4 of each week
75 mg/m2 once daily
6 150 mg once daily
Days 1–5 of each week
75 mg/m2 once daily
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further 4 weeks of olaparib at the same dose. Olaparib treatment
will be continuous and the daily dose will be escalated based on
a 3 + 3 phase I design. Patients in parallel II will receive neither
concomitant nor adjuvant temozolomide; the dose escalation
strategy for olaparib is shown in Table 2.
PARADIGM-2 targets a population of patients with newly diag-
nosed GBM who meet the NICE TA23 eligibility criteria for treat-
ment with radical radiotherapy and concomitant temozolomide.
Approximately 44–68 patients across both parallels will be
recruited. Potential patients will be identified at neuro-oncology
multi-disciplinary team meetings in participating centres.Rationale for study design
Several randomised phase III trials have demonstrated the prog-
nostic and predictive value of MGMT promoter region methylation
as a robust molecular biomarker in GBM [2,5,6]. Patients whose
tumours exhibit methylation of the MGMT promoter region have
better prognosis and derive clinical benefit from the addition of
temozolomide to radiotherapy. In contrast, patients whose
tumours exhibit unmethylated MGMT promoter regions have
poorer prognosis and derive no benefit from the addition of temo-
zolomide to standard radiotherapy [3,20]. The MGMT unmethy-
lated group represents approximately 55% of cases and is a
population with particularly pressing unmet clinical need. Current
clinical practice is to treat all patients with concomitant and adju-
vant temozolomide, regardless of MGMT status. In the context of a
clinical trial, however, it is widely accepted that temozolomide can
be safely and ethically omitted in patients with MGMT unmethy-
lated tumours, as long as an alternative treatment is offered [21].
Several commercial and investigator led studies have demon-
strated the feasibility and acceptability of this approach.
In PARADIGM-2, therefore, treatment will be informed by
MGMT methylation status. Patients whose tumours haveTable 2
Dose escalation strategy for MGMT unmethylated patients.
Dose
level
Olaparib dose starting three days prior to radiotherapy and
continuing until 4 weeks afterwards
1 50 mg once daily, continuous
2 100 mg once daily, continuous
3 100 mg twice daily, continuous
4 200 mg twice daily, continuousunmethylated MGMT promoter regions will be treated with radio-
therapy and olaparib, without temozolomide. This approach liber-
ates these patients from the haematological toxicity associated
with olaparib-temozolomide combination therapy, allowing con-
tinuous daily olaparib dosing in tandem with daily radiotherapy
fractions. Patients with MGMT methylated tumours derive clear
benefit from temozolomide and will receive olaparib with radio-
therapy in addition to concomitant and adjuvant temozolomide.
Inclusion criteria for PARADIGM-2 study
 Age < 70 years
 Histologically confirmed diagnosis of glioblastoma (WHO grade
IV)
 WHO performance status 0 or 1
 Sufficient tumour material for MGMT promoter methylation
assay
 Life expectancy greater than 12 weeks
 No previous radiotherapy for primary or secondary CNS
malignancy
 Adequate haematological, hepatic and renal function
 Able to commence radiotherapy treatment within 6 weeks (±1
week) of surgery
 Willingness to comply with scheduled visits, treatment plans,
laboratory tests and other trial related procedures
 Able to swallow trial medications
 Evidence of non-child bearing status for women of child-
bearing potential
Exclusion criteria for PARADIGM-2 study
 Active concomitant malignancy
 Prior treatment for primary or secondary CNS malignancy
 Confusion or altered mental state that would prohibit under-
standing and giving of informed consent
 Any previous treatment with a PARP inhibitor, including
olaparib
 Any red blood cell transfusions within 28 days
 Patients with myelodysplastic syndrome or acute myeloid
leukaemia
 Patients with uncontrolled seizures
Study objectives and end-points
The overall hypothesis is that combining olaparib with radio
therapy ± temozolomide will improve outcomes for patients with
newly diagnosed GBM, without significantly exacerbating toxicity.
The primary objective of parallel I (MGMT methylated) is to
establish the safety, toxicity, maximum tolerated dose (MTD) and
optimum schedule of olaparib in combination with radical radio-
therapy and concomitant temozolomide in patients with newly
diagnosed GBM, with which to proceed to a randomized phase II
study.
The primary objective of parallel II (MGMT unmethylated) is to
establish the safety, toxicity, MTD and optimum schedule of ola-
parib in combination with radical radiotherapy in patients with
newly diagnosed GBM, with which to progress to a randomized
phase II study.
Secondary objectives for both parallels are:
 Define dose-limiting toxicities associated with olaparib in com-
bination with radiotherapy ± temozolomide.
 Obtain preliminary information on the impact of this regime on
acute and sub-acute neurotoxicity
 Obtain preliminary evidence of efficacy of the regimens, in
terms of progression-free survival and overall survival.
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ria for Adverse Events (CTCAE) scoring system, version 4.03. Defini-
tions of dose limiting toxicity are listed in Table 3.
Patients recruited into the trial will be invited to authorize use
of blood samples and surplus tumour tissue for translational
research projects. The main aims of these projects will be to iden-
tify molecular biomarkers with potential to predict which patients
will benefit from the addition of olaparib to radiotherapy ±
temozolomide.Radiotherapy Quality Assurance
Radiotherapy Quality Assurance (RTQA) in PARADIGM-2 will be
conducted through the UK RTTQA team. Pre-trial participation
questionnaires will be sent to participating sites to collate informa-
tion on staffing, equipment and delivery technique details. Each
site will then be required to submit a ‘dummy-run’ case, compris-
ing a case chosen by the site that has been outlined and planned as
per trial protocol. Radiotherapy dosimetry and treatment data will
be collected on all patients participating in the trial.Duration of trial participation
Parallel I: patients will be assessed 4 weeks after the final frac-
tion of radiotherapy, at which point they will commence adjuvant
temozolomide, during which they will be assessed every 4 weeks.
Upon completion or discontinuation of temozolomide, patients
will enter follow-up and be assessed every 3 months or until clin-
ical or radiological disease progression. Once date of progression
has been recorded, patients will be followed up locally to establish
overall survival.
Parallel II: patients in parallel II will be assessed 4 weeks after
the final fraction of radiotherapy and then a further 8 weeks later,
after which they will be assessed every 3 months or until clinical or
radiological progression. After progression, patients will be fol-
lowed up locally to establish overall survival.Trial analysis plan
Dose escalation of olaparib in both parallels will follow a 3 + 3
cohort design but also take into account data from the current
and all previous cohorts, enabling dose escalation decisions to be
informed by late emerging adverse events. The study will explore
cohorts until the MTD or recommended dose and schedule of ola-
parib has been determined.Table 3
Definitions of dose limiting toxicities.
MGMT methylated and unmethylated patients
Failure to complete radiotherapy because of toxicity, as considered by the investigator
tumour progression).
Any grade  3 non-haematological toxicity (see appendix CTCAE 4.03) that was not pr
in consultation with the SRC, is due to olaparib or the combination of olaparib and
of olaparib treatment until the end of olaparib treatment (ie. 4 weeks after the en
Neutropenia grade 4that persists for 5 days and occurs during the olaparib treatme
Febrile neutropenia grade  3 (absolute neutrophil count <1.0  109/L and fever 38
Thrombocytopenia grade 4 which persists for  5 days or is associated with active ble
period.
Failure to complete >75% of planned olaparib treatment at the prescribed dose becau
MGMT methylated patients only
Failure to complete concomitant temozolomide chemotherapy because of toxicity, as c
of tumour progression).
Any toxicities grade 3 occurring during adjuvant temozolomide will not be conside
temozolomide and olaparib will be considered a DLT. The evaluable DLT period enParallel I: Up to 6 cohorts of 3–6 patients. The final cohort will
be expanded to include 10 patients. The estimated sample size is
25–40 patients.
Parallel II: Up to 4 cohorts of 3–6 patients. The final cohort will
be expanded to include 10 patients. The estimated sample size is
19–28 patients.
Data analysis of data will be descriptive, summarizing toxicities
and dose-limiting toxicities by dose escalation cohort. Details of
treatment delivery will be summarized and worst grade of toxicity
during olaparib treatment tabulated. Secondary endpoints (overall
survival and progression-free survival) will be summarized by
individual cohort using techniques appropriate to the number of
patients available. Data from expansion cohorts will be presented
as Kaplan-Meier analyses.
Discussion
Previous attempts at radiotherapy dose escalation have failed to
demonstrate clinical benefit [4–6] for patients with GBM and there
remains a clinical need to improve outcomes. PARADIGM-2 offers a
novel approach to previous studies in this area by combining a
potent, tumour specific radiosensitising agent with conventional
radiotherapy or radiochemotherapy. Another novel aspect is the
use of MGMT promoter region methylation status to individualise
treatment. The DNA damage response targeting approach adopted
in this study also avoids the potential pitfalls of targeting individ-
ual oncogenic signaling pathways, which has been shown to be
ineffective in this heterogeneous and genetically complex disease
[7].
Multiple phase III trials have demonstrated the prognostic and
predictive value of MGMT promoter region methylation status in
patients with GBM [2]. The design of PARADIGM-2 aligns with
recent clinical trials that have demonstrated the acceptability of
omitting temozolomide in patients with MGMT unmethylated
tumours [21]. This reduces the risk of haematological toxicity
and will enable continuous olaparib dosing with a view to max-
imising tumour control.
Patients will be asked to consent to collection of surplus tissue
for translational research. These translational studies will exploit
the research team’s expertise in DNA damage response (DDR) biol-
ogy to undertake preliminary evaluation of a panel of candidate
predictive biomarkers. Based on published data demonstrating
that the radiosensitising effects of olaparib are enhanced in the
presence of DDR defects, this research will evaluate correlations
between clinical outcomes and a panel of Immunohistochemical
markers of DNA replication and cellular proliferation. Further
translational end points will focus on the correlation of genomic
instability with DDR defects and the novel, unpublished observa-in consultation with the safety review committee (SRC) (i.e. with no evidence of
esent prior to commencing olaparib and which, in the opinion of the investigator
radiotherapy (±temozolomide). Such toxicities will be classed as a DLT from start
d of radiotherapy treatment).
nt period.
.5 C) that occurs during the olaparib treatment period.
eding or requiring platelet transfusion and occurs during the olaparib treatment
se of toxicity.
onsidered by the investigator in consultation with the SRC (i.e. with no evidence
red a DLT. However any toxicity grade 3 deemed due to interaction between
ds after cycle 1 of adjuvant temozolomide.
16 B. Fulton et al. / Clinical and Translational Radiation Oncology 8 (2018) 12–16tion that primary cell lines derived from genomically unstable
tumours show enhanced radio-sensitisation responses to PARP
inhibitors.
If the olaparib-radiotherapy combination is tolerated by MGMT
unmethylated patients and the MTD of olaparib is determined to
be 100 mg twice daily or greater, we will aim to proceed to a ran-
domized phase II study in this patient population. If the olaparib-
radiotherapy-temozolomide combination is tolerated in MGMT
methylated patients and olaparib can safely be delivered on at least
three days per week we will aim to proceed to a randomized phase
II study in this population.
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